Table 1 Biological roles of insulin-like growth factor binding protein 5 (IGFBP-5) in different types of cancer
From: Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer
| Cancer type | Source of tissue or cell line | Application of the study or study design | Observed functional effects of IGFBP-5 | Ref. |
|---|---|---|---|---|
| Breast | T47D | Intracellular trafficking | Nuclear localization of IGFBP-5 | [31] |
| Hs578T | Analysis of mitogenic effect of IGFBP-5 | Protective effect against ceramide-induced apoptosis | [104] | |
| Hs578T | Cell attachment applications | Cell attachment increased by exogenously added IGFBP-5 | [110] | |
| MDA-MB-231 | Cellular localization and apoptotic role of IGFBP-5 | IGFBP-5 localizes in the nucleus and produces apoptosis | [107] | |
| MDA-MB-231 | Role of IGFBP-5 in the apoptotic pathway | IGFBP-5 induces and activates caspase 8 and caspase 9 | [108] | |
| Neuroblastoma | B104 | Characterization of IGFBP-5 proteases | A specific serine-metalloprotease for IGFBP-5 | [122] |
| LAN-5, N1E-115 | Analysis of IGFBP-5 promoter sites | c-Myb and B-Myb enhance IGFBP-5 transcription | [45] | |
| LAN-5, SY5Y(N) | Micro and small interfering RNAs directed to IGFBP-5 mRNA | Growth inhibition and more prone to apoptosis | [123] | |
| Various types of neuroblastoma cells | Retinoic acid-induced differentiation | Increased expression of IGFBP-5 | [47, 124] | |
| LAN-5, SY5Y(N) | Silencing IGFBP-5 | Mitochondrial apoptosis | [125] | |
| Prostate | CWR22, CaP xenograft | Castration and androgen stimulation | Androgen receptor upregulates IGFBP-5 | [126] |
| Mouse androgen-dependent Shionogi tumor model | Castration-induction | Upregulation of IGFBP-5 | [97] | |
| LNCaP PC-3 | Hormone treatment 1α,25(OH)2D3 treatment | No significant effect on IGFBP-5 mRNA level | [127] | |
| IGFBP-5 is primary target gene of the 1 α,25(OH)2D3 | [128] | |||
| Bone marrow stromal cells | Androgen suppression treatment | Increasing IGFBP-5 mRNA expression facilitates prostate cancer progression | [129] | |
| Osteosarcoma | Osteosarcoma U2 cell line, untrans-formed normal human bone cells | Proteolytic degradation of IGFBP-4 and IGFBP-5 | Proteolytic activity of IGFBP-5 can modulate IGF action in bone | [130] |
| Rat osteosarcoma cells | Relationship between growth hormone receptor and IGFBP-5 | IGFBP-5 increases growth hormone receptor mRNA and growth hormone binding and potentiates mitogenesis | [131] | |
| OS/50-K8 mouse osteosarcoma cells | Biological activity of IGFBP-5 | IGFBP-5 reduces proliferation and regulates differentiation | [132] | |
| U2 human osteosarcoma cells | Examination of IGFBP-5 proteases | ADAM-9 cleaved IGFBP-5 specifically and is v | [133] | |
| Bone cells | Silencing of IGFBP-5 | Knockdown of IGFBP-5 induced DNA synthesis and reduced differentiation | [134] | |
| U2 human osteosarcoma cells | Detection of IGFBP-5 interacting proteins | A novel IGFBP-5 interacting protein (IGFBP5-IP) | [135] | |
| LSaOS human osteosarcoma cell line | IGFBP-5 regulations in bone | Four-and-a-half LIM protein 2 and ADAM-9 are major modulators of IGFBP-5 actions | [136] | |
| Ovarian | Human ovarian carcinoma lines | IGFBP levels | Expression of IGFBP-5 appears as a rather rare event | [137] |
| Ovarian | Various types of ovarian cancers | Examine IGFBP-2 and IGFBP-5 levels | Overexpression of IGFBP-5 in high-grade ovarian carcinoma | [138] |
| Ovarian cancer patients | Evaluate predictive value of IGFBPs in aromatase inhibitor letrozole | IGFBP-5 is a predictive marker for endocrine therapy | [139] | |
| Cervical | HPV(-) C33A, HPV(+) CaSki cells | Retinoic acid treatment | IGFBP-5 overexpression determines retinoic acid effects in human papilloma virus(-) cells | [48] |
| Squamous cell carcinomas | Cervical carcinogenesis | Downregulation of IGFBP-5 | [140] | |
| Colon | LoVo cells | NS398 treatment | IGFBP-5 might be a target of NS398 | [141] |
| Colon epithelial cells | Leptin treatment | Downregulation of IGFBP-5 by leptin treatment | [142] | |
| Renal | Oncocytomas, clear cell and papillary renal cell carcinoma | Changes of IGF/IGFBPs | Downregulation of IGFBP-5 in papillary renal cell carcinoma and oncocytomas | [143] |
| Clear cell renal cell carcinoma | Analysis of IGF-axis components | Downregulation of IGFBP-5 | [144] | |
| Lung | Lun squamous cell carcinomas, and normal bronchial epithelial tissues | Identification of differentially expressed genes | Overexpression of IGFBP-5 | [145] |
| Gastric | A panel of human gastric cancer cell lines, and normal and tumor tissues | Detect IGFs and IGFBP levels | One-half of the tumor cells express IGFBP-5 | [146] |
| Thyroid | Various types of thyroid tissues | IGFBP-5 levels | Overexpression of IGFBP-5 in papillary carcinoma | [98] |
| Pancreas | Pancreatic ductal adenocarcinoma | Differential expression of genes | Overexpression of IGFBP-5 | [147] |